Remibrutinib (LOU064) treatment improves chronic spontaneous urticaria in patients irrespective of previous anti-IgE treatment: Phase 2b study results

被引：0
|
作者：
Metz, M. [1 ,2 ,3 ,4 ]
Greiner, A. [5 ,6 ]
Guduri, S. [7 ]
Leflein, J.
Haemmerle, S. [8 ]
Lheritier, K. [8 ]
Walsh, P. [9 ]
Nikolaev, I. [8 ]
Gimenez-Arnau, A. M. [10 ]
Maurer, M. [1 ,2 ,3 ,4 ]
机构：
[1] Inst Allergol, UCARE, Berlin, Germany
[2] Freie Univ, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Fraunhofer Inst Translat Med & Pharmacol ITMP, Allergol & Immunol, Berlin, Germany
[5] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA
[6] Univ Calif San Diego, San Diego, CA USA
[7] Centricity Res Inc, Columbus, OH USA
[8] Novartis Pharma AG, Basel, Switzerland
[9] Novartis Ireland Ltd, Dublin, Ireland
[10] Univ Pompeu Fabra, Dept Dermatol, Hosp Mar IMIM, Barcelona, Spain
来源：
ALLERGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
000883
引用
收藏
页码：245 / 246
页数：2
相关论文
共 50 条
  • [41] Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study
    Dickson, Marion C.
    Walker, Alexandra
    Grattan, Clive
    Perry, Hayley
    Williams, Nicola
    Ratia, Nirav
    Dewit, Odile
    Gisbert, Sophie
    Metz, Martin
    Maurer, Marcus
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (12) : 4797 - 4808
  • [42] Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: Primary results of a placebo- and active-controlled phase 2b dose finding study
    Maurer, M.
    Gimenez-Arnau, A.
    Sussman, G.
    Loeffler, J.
    Barve, A.
    Severin, T.
    Janocha, R.
    ALLERGY, 2018, 73 : 837 - 837
  • [43] Effect of Linaclotide On IBS-Symptoms in the First Week of Treatment: Results from a Phase 2B Study
    Lembo, Anthony J.
    Johnston, Jeffrey M.
    Lavins, Bernard J.
    MacDougall, James E.
    Schneier, Harvey
    Shiff, Steven J.
    Kurtz, Caroline B.
    Currie, Mark G.
    GASTROENTEROLOGY, 2009, 136 (05) : A30 - A31
  • [44] Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study
    Glorieux, Francis H.
    Langdahl, Bente
    Chapurlat, Roland
    De Beur, Suzanne Jan
    Sutton, Vernon Reid
    Poole, Kenneth E. S.
    Dahir, Kathryn M.
    Orwoll, Eric S.
    Willie, Bettina M.
    Mikolajewicz, Nicholas
    Zimmermann, Elizabeth
    Hosseinitabatabaei, Seyedmahdi
    Ominsky, Michael S.
    Saville, Chris
    Clancy, James
    Macinnon, Alastair
    Mistry, Arun
    Javaid, Muhammad K.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 (09) : 1215 - 1228
  • [45] Efficacy and Safety of Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 DoseRanging Study
    Maurer, Marcus
    Gimenez-Arnau, Ana
    Ferrucci, Silvia
    Mikol, Vincent
    Sun, Iris
    Mannent, Leda
    Gereige, Jessica
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB373 - AB373
  • [46] Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: primary results of a placebo- and active-controlled phase 2b dose-finding study
    Maurer, M.
    Gimenez-Arnau, A.
    Sussman, G.
    Loeffler, J.
    Barve, A.
    Severin, T.
    Janocha, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 121 - 121
  • [47] Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)
    Chan, Henry L. Y.
    Ahn, Sang Hoon
    Chang, Ting-Tsung
    Peng, Cheng-Yuan
    Wong, David
    Coffin, Carla S.
    Lim, Seng Gee
    Chen, Pei-Jer
    Janssen, Harry L. A.
    Marcellin, Patrick
    Serfaty, Lawrence
    Zeuzem, Stefan
    Cohen, David
    Critelli, Linda
    Xu, Dong
    Wind-Rotolo, Megan
    Cooney, Elizabeth
    JOURNAL OF HEPATOLOGY, 2016, 64 (05) : 1011 - 1019
  • [48] Results of a phase 2B study of the humanized anti-C5 antibody eculizumab in patients with rheumatoid arthritis
    Mojcik, CF
    Kremer, J
    Bingham, C
    Burch, F
    Vitiello, S
    McCroskery, E
    Bookbinder, S
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 301 - 301
  • [49] Interleukin-2 plus ribavirin versus interferon-α-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-α-2b treatment
    Malaguarnera, M
    Pistone, G
    Neri, S
    Romano, M
    Brogna, A
    Musumeci, S
    BIODRUGS, 2004, 18 (06) : 407 - 413
  • [50] Interleukin-2 Plus Ribavirin Versus Interferon-α-2b Plus Ribavirin in Patients with Chronic Hepatitis C Who Did Not Respond to Previous Interferon-α-2b Treatment
    Mariano Malaguarnera
    Giovanni Pistone
    Sergio Neri
    Marcello Romano
    Alfio Brogna
    Salvatore Musumeci
    BioDrugs, 2004, 18 : 407 - 413
12345